Sulindac treatment in hereditary non-polyposis colorectal cancer

European Journal of Cancer

Volumn 43, Issue 8, 2007, Pages 1251-1256

  Rijcken, Fleur E M ^a   Hollema, Harry ^a   van der Zee, Ate G J ^a   van der Sluis, Tineke ^a   Boersma van Ek, Wytske ^a   Kleibeuker, Jan H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apoptosis; Chemoprevention; HNPCC; Proliferation; Sulindac

Indexed keywords

CYCLIN B1; CYCLIN D3; CYCLIN E; CYCLOOXYGENASE 2; CYTOKERATIN 18; KI 67 ANTIGEN; PLACEBO; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; SULINDAC;

ABDOMINAL CRAMP; ADULT; AGED; APOPTOSIS; ARTICLE; ASCENDING COLON; CANCER RISK; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLON BIOPSY; COLON MUCOSA; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECTUM BIOPSY; SIGMOID; TRANSVERSE COLON;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; SULINDAC;

EID: 34248144405     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.03.001     Document Type: Article

References (28)

1. Lynch H.T., and de la Chapelle C.A. Hereditary colorectal cancer. New Engl J Med 348 (2003) 919-932
2. Kinzler K.W., and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87 (1996) 159-170
3. Hanif R., Pittas A., Feng Y., et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 52 (1996) 237-245
4. Brown W.A., Skinner S.A., Malcotenti-Wilson C., Vogiagis D., and O'Brien P.E. Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation. Gut 48 (2001) 660-666
5. Giardiello F.M., Hamilton S.R., Krush A.J., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. New Engl J Med 328 (1993) 1313-1316
6. Baron J.A., Cole B.F., Sandler R.S., et al. A randomized trial of aspirin to prevent colorectal adenomas. New Engl J Med 348 (2003) 891-899
7. Janne P.A., and Mayer R.J. Chemoprevention of colorectal cancer. New Engl J Med 342 (2000) 1960-1968
8. Thun M.J., Henley S.J., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94 (2002) 252-266
9. Cruz-Correa M., Hylind L.M., Romans K.E., Booker1 S.V., and Giardiello F.M. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 122 (2002) 641-645
10. Giovannucci E., Egan K.M., Hunter D.J., et al. Aspirin and the risk of colorectal cancer in women. New Engl J Med 333 (1995) 609-614
11. Labayle D., Fischer D., Vielh P., et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101 (1991) 635-639
12. Shiff S.J., Qiao L., Tsai L.L., and Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 96 (1995) 491-503
13. Shiff S.J., Koutsos M.I., Qiao L., and Rigas B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 22 (1996) 179-188
14. Dannenberg A.J., Altorki N.K., Boyle J.O., et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2 (2001) 544-551
15. Qiao L., Shiff S.J., and Rigas B. Sulindac sulfide alters the expression of cyclin proteins in HT-29 colon adenocarcinoma cells. Int J Cancer 76 (1998) 99-104
16. Poole J.C., Thain A., Perkins N.D., and Roninson I.B. Induction of transcription by p21Waf1/Cip1/Sdi1: role of NFkappaB and effect of non-steroidal anti-inflammatory drugs. Cell Cycle 3 (2004) 931-940
17. Zhang L., Yu J., Park B.H., Kinzler K.W., and Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 290 (2000) 989-992
18. Yang W., Velcich A., Mariadason J., et al. p21(WAF1/cip1) is an important determinant of intestinal cell response to sulindac in vitro and in vivo. Cancer Res 61 (2001) 6297-6302
19. Vasen H.F., Mecklin J.P., Khan P.M., and Lynch H.T. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34 (1991) 424-425
20. Vasen H.F., Watson P., Mecklin J.P., and Lynch H.T. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116 (1999) 1453-1456
21. Goldberg Y., Nassif I.I., Pittas A., et al. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 12 (1996) 893-901
22. Nugent K.P., Farmer K.C., Spigelman A.D., Williams C.B., and Phillips R.K. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 80 (1993) 1618-1619
23. Spagnesi M.T., Tonelli F., Dolara P., et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 106 (1994) 362-366
24. Pasricha P.J., Bedi A., O'Connor K., et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 109 (1995) 994-998
25. Winde G., Schmid K.W., Brandt B., Muller O., and Ossawald H. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis Colon Rectum 40 (1997) 1156-1168
26. Moorghen M., Orde M., Finney K.J., Appleton D.R., and Watson A.J. Sulindac enhances cell proliferation in DMH-treated mouse colonic mucosa. Cell Prolif 31 (1998) 59-70
27. Keller J.J., Offerhaus G.J., Polak M., et al. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Gut 45 (1999) 822-828
28. Keller J.J., Offerhaus G.J., Hylind L.M., and Giardiello F.M. Rectal epithelial apoptosis does not predict response to sulindac treatment or polyp development in presymptomatic familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 11 (2002) 670-671